Globela Pharma is a finished-dose manufacturer based in India. It appears in 188 regulatory filings across 8 regulators, without an active US DMF or CEP on file. Its filings concentrate with NAFDAC (NG), ARCSA (EC) and DIGEMAPS (DO). Its GMP standing is certified by CDSCO (India) and EMA. Customs aggregates show $28.6M of exports covering 1,331 molecules to 45 destinations in 2025.
| Site | FDA FEI |
|---|---|
| sachin surat 394 230, India | Not on file |
| G.I.D.C., India | Not on file |
| Surat, India | Not on file |
| G.I.D.C., India | Not on file |
| tal umbergaonvalsad 396 105, India | Not on file |
| valsad, India | Not on file |
| Regulator | Filings | GMP certificates |
|---|---|---|
| NAFDAC (NG) | 139 | None |
| ARCSA (EC) | 30 | None |
| DIGEMAPS (DO) | 11 | None |
| EFDA (ET) | 3 | None |
| BOMRA (BW) | 2 | None |
| MINSA (CR) | 1 | None |
| CDSCO (India) | None | 6 |
| EMA | None | 2 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $3K | 1 |
| 2025 | Not reported | $28.6M | 45 |
| 2024 | Not reported | $23.0M | 45 |
| 2023 | Not reported | $20.1M | 37 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Globela Pharma comes back tiered against every other supplier able to file there.
Start for free